Trials / Unknown
UnknownNCT04878705
Safety and Tolerability of TWP-201 in Healthy Female Subjects
A Randomized, Double-blind, Placebo-controlled, Single Dose, Escalation, Phase I Clinical Trial to Evaluate the Safety and Tolerability of TWP-201 in Healthy Female Subjects
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (estimated)
- Sponsor
- Shandong TheraWisdom Biopharma Co., Ltd. · Industry
- Sex
- Female
- Age
- 18 Years – 42 Years
- Healthy volunteers
- Accepted
Summary
This study is a randomized, double-blind, placebo-controlled, single dose, escalation, phase I clinical trial to evaluate the safety and tolerability of recombinant human follicle stimulating hormone Fc fusion protein injection (TWP-201) in healthy female subjects. The objective of the trial is to evaluate the safety and tolerability of TWP-201 in healthy female subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TWP-201 | a single subcutaneous injection |
| DRUG | placebo | a single subcutaneous injection |
Timeline
- Start date
- 2021-05-17
- Primary completion
- 2022-10-31
- Completion
- 2022-12-31
- First posted
- 2021-05-07
- Last updated
- 2021-07-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04878705. Inclusion in this directory is not an endorsement.